Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment

Diabetes Care

Volumn 33, Issue 8, 2010, Pages 1706-1711

  Abbatecola, Angela M ^a   Lattanzio, Fabrizia ^a   Molinari, Anna M ^b   Cioffi, Michele ^b   Mansi, Luigi ^b   Rambaldi, Pierfrancesco ^b   DiCioccio, Luigi ^c   Cacciapuoti, Federico ^b   Canonico, Raffaele ^b   Paolisso, Giuseppe ^b  

^a INRCA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Santa Scolastica Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE;

AGED; ARTICLE; COGNITION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PSYCHOLOGIC TEST;

AGED; AGED, 80 AND OVER; COGNITION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLIDINEDIONES;

EID: 77958173794     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2030     Document Type: Article

References (25)

1. Messier C, Gagnon M. Cognitive decline associated with dementia and type 2 diabetes: the interplay of risk factors. Diabetologia 2009;52:2471-2474
2. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, Vella A, Rocca WA, Petersen RC. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008;65:1066-1073
3. Biessels GJ, Kappelle LJ, Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 2005;33:1041-1044
4. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006;29:345-351
5. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001;108: 1341-1348 (Pubitemid 33107762)
6. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, Acampora R, Passariello N, Cacciapuoti F, Paolisso G. Post prandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006;67: 235-240 (Pubitemid 44305405)
7. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 2004;490:97-113 (Pubitemid 38482164)
8. Folli F, Ghidella S, Bonfanti L, Kahn CR, Merighi A. The early intracellular signaling pathway for the insulin/insulin-like growth factor receptor family in the mammalian central nervous system. Mol Neurobiol 1996;13:155-183 (Pubitemid 126719025)
9. Folli F, Bonfanti L, Renard E, Kahn CR, Merighi A. Insulin receptor substrate-1 (IRS-1) distribution in the rat central nervous system. J Neurosci 1994;14:6412-6422
10. Abbatecola AM, Paolisso G, Lamponi M, Bandinelli S, Lauretani F, Launer L, Ferrucci L. Insulin resistance and executive dysfunction in older persons. J Am Geriatr Soc 2004;52:1713-1718
11. Rönnemaa E, Zethelius B, Sundelöf J, Sundström J, Degerman-Gunnarsson M, Berne C, Lannfelt L, Kilander L. Impaired insulin secretion increases the risk of Alzheimer disease. Neurology 2008;71: 1065-1071
12. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005;13:950-958
13. Mancia G, Grassi G. The new European Society of Hypertension/European Society of Cardiology (ESH/ESC) Guidelines. Ther Adv Cardiovasc Dis. 2008;2:5-12
14. Brown PJ, Woods CM, Storandt M. Model stability of the 15-item Geriatric Depression Scale across cognitive impairment and severe depression. Psychol Aging 2007;22:372-379
15. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-194
16. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. Public Health Nutr 2003;6:407-413
17. Lezak M, Howieson D, Loring D. Neuropsychological Assessment. 4th ed. Oxford, U.K., Oxford University Press, 2004; pp 381-384, 438-445, 741-744
18. Ratcliff G, Dodge H, Birzescu M, Ganguli M. Tracking cognitive functioning over time: ten-year longitudinal data from a community-based study. Appl Neuropsychol 2003;10:76-88
19. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) trial. Diabetes Care 2009;32:221-226
20. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav Brain Res 1996;75:1-11
21. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-4167
22. Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J Am Geriatr Soc. 2009;57:177-179
23. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J, PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865-873
24. Open-label extension study of rosiglitazone XR as adjunctive therapy in subjects with mild-to-moderate Alzheimers [article online], 2010. Available from http://www. clinicaltrials.gov/ct2/show/NCT00490568? term= rosiglitazone+and+alzheimer%27s+ disease&rank=7. Accessed 01 October 2009
25. Study of rosiglitazone XR in subjects with mild-to-moderate Alzheimers [article online], 2010. Available from http://www. clinicaltrials.gov/ct2/show/ NCT00550420? term=rosiglitazone+and+alzheimer%27s+ disease&rank=9. Accessed 01 October 2009